Blood-testing startup faked tests to dupe investors: Lawsuit
Court documents have revealed that blood-testing startup Theranos, which was once valued at $9 billion, ran fake 'demonstration tests' for prospective investors. The complaint is based on testimony from 22 former employees and directors and claims that Theranos used commercial devices instead of its one-drop blood testing technology to cheat investors and business partners.